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Abstract
Background: The Evaluating Xience and left ventricular function in PCI on occlusiOns afteR STEMI (EXPLORE) trial
did not show a significant benefit of percutaneous coronary intervention (PCI) of the concurrent chronic total
occlusion (CTO) in ST-segment elevation myocardial infarction (STEMI) patients on global left ventricular (LV) systolic
function. However a possible treatment effect will be most pronounced in the CTO territory. Therefore, we aimed
to study the effect of CTO PCI compared to no-CTO PCI on the recovery of regional LV function, particularly in the
CTO territory.
Methods: Using cardiovascular magnetic resonance (CMR) we studied 180 of the 302 EXPLORE patients with serial
CMR (baseline and 4 months follow-up). Segmental wall thickening (SWT) was quantified on cine images by an
independent core laboratory. Dysfunctional segments were defined as SWT < 45%. Dysfunctional segments were
further analyzed by viability (transmural extent of infarction (TEI) ≤50%.). All outcomes were stratified for
randomization treatment.
Results: In the dysfunctional segments in the CTO territory recovery of SWT was better after CTO PCI compared to
no-CTO PCI (ΔSWT 17 ± 27% vs 11 ± 23%, p = 0.03). This recovery was most pronounced in the dysfunctional but
viable segments(TEI < 50%) (ΔSWT 17 ± 27% vs 11 ± 22%, p = 0.02). Furthermore in the CTO territory, recovery of
SWT was significantly better in the dysfunctional segments in patients with Rentrop grade 2–3 collaterals compared
to grade 0–1 collaterals to the CTO (16 ± 26% versus 11 ± 24%, p = 0.04).
Conclusion: CTO PCI compared with no-CTO PCI is associated with a greater recovery of regional systolic function in
the CTO territory, especially in the dysfunctional but viable segments. Further research is needed to evaluate the use of
CMR in selecting post-STEMI patients for CTO PCI and the effect of regional LV function recovery on clinical outcome.
Trial registration: Trialregister.nl NTR1108, Date registered NTR: 30-okt-2007.
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Background
ST-segment elevation myocardial infarction (STEMI) pa-
tients with a concurrent chronic total occlusion (CTO),
found in 10–15% of STEMI patients, have a remarkably
higher mortality and morbidity [1, 2]. In STEMI patients
with a concurrent CTO, the Evaluating Xience and left
ventricular function in PCI on occlusiOns afteR STEMI
(EXPLORE) was the first randomized trial that com-
pared CTO percutaneous coronary intervention (PCI)
within one week after STEMI versus no-CTO PCI
within 4 months. This study showed that CTO PCI
compared to no-CTO PCI did not result in a higher left
ventricular (LV) ejection fraction (EF) and lower left
ventricular end-diastolic volume (LVEDV) measured by
cardiovascular magnetic resonance (CMR) at 4 months
follow-up (FU) [3]. An in-depth analysis on the recovery
of global LV function (comparing LV function at baseline
to 4 month) in 180 patients with serial CMR showed
that there was no treatment effect of CTO PCI[4]. The
primary endpoints of EXPLORE were global LVEF and
LVEDV which are parameters that are affected by many
other factors, especially in the early post-STEMI phase.
A possible treatment effect of CTO PCI will however be
most pronounced in the CTO territory. We therefore
aimed to perform an in-depth quantitative analysis of
the regional function of the myocardium supplied by the
CTO. CMR allows for accurate analysis of regional
segmental function (segmental wall thickening (SWT))
[5, 6]. In elective setting, successful CTO PCI has been
associated with significant improved regional wall mo-
tion over time, especially in dysfunctional but viable
segments (transmural extent of infarction (TEI) <50%)
[6, 7]. However the effect of CTO PCI on regional func-
tion has never been compared to a control group (no-
CTO PCI) and it has not been investigated in STEMI
patients with a concurrent CTO. Therefore in this EX-
PLORE CMR study we aimed to study the effect of CTO
PCI compared to no-CTO PCI on the recovery of re-
gional LV function, particularly in the CTO territory.
Methods
Patients and treatment
The design and main results of the EXPLORE trial were
described in detail previously [3]. Briefly, the EXPLORE
study was a randomized multi-centre clinical trial in
which STEMI patients with a concurrent CTO (n = 302)
between 2007 and 2015 were randomly assigned in a 1:1
ratio to CTO PCI within 7 days after primary PCI
(n = 148) or to a conservative strategy (no-CTO PCI)
for at least 4 months (n = 154). Patients were eligible if
during successful primary PCI a concurrent CTO was
found in a non-infarct related artery (IRA). Important
exclusion criteria were >48 h hemodynamically instabil-
ity and conditions impeding CMR imaging such as renal
failure, atrial fibrillation and indication for pacemaker or
implantable cardioverter-defibrillator (ICD) within
4 months after randomization. The primary endpoints of
the trial were LVEF and LVEDV at 4 months follow-up
measured on CMR. At 4 months follow-up there was no
significant difference on LV function between patients
randomized to CTO PCI and patients randomized to
no-CTO PCI (LVEF: 44.1 ± 12.2% vs. 44.8 ± 11.9%,
p = 0.60 and LVEDV 215.6 ± 62.5 ml versus
212.8 ± 60.3 ml, p = 0.70). Also, no significant differ-
ences in the secondary endpoints of left ventricular sys-
tolic volume, left ventricular mass and infarct size were
observed. CTO was defined as a 100% luminal narrow-
ing without antegrade flow or with antegrade or retro-
grade filling through collaterals. The coronary vessel in
which the CTO was located should have a reference
diameter of at least 2.5 mm. For patients with multiple
CTOs, the main CTO was defined as the CTO supply-
ing the largest amount of myocardium. All coronary an-
giographies were evaluated by an independent
angiography corelab to assess location and characteris-
tics of culprit lesion, CTO lesions and quality of the col-
laterals. Collateral quality assessment was done at the
baseline angiogram (primary PCI). Presence and extent
of retrograde collateral flow was determined using the
Rentrop classification score [8]. Patients were divided
into 2 groups: patients with angiographic grade 0 or 1
collaterals to the CTO and patients with angiographic
grade 2 or 3 collaterals to the CTO territory. If a patient
had ≥1 collateral to the CTO, the collateral with the
highest score was used. The current study cohort in-
cludes 180 of the 302 included EXPLORE patients and is
a substudy performed in patients with serial CMR (base-
line and 4 months FU) and this cohort has been de-
scribed before [4]. The primary outcome of this
EXPLORE substudy is recovery of regional LV function
(SWT %) from baseline to 4 months follow-up defined
as change in SWT, specifically measured in the CTO
supplied territory. Furthermore we assessed the effect of
CTO PCI in the dysfunctional but viable segments and
the effect of collaterals on regional LV function.
Cardiovascular magnetic resonance protocol
CMR was performed on a 1.5-Tesla scanner using a ded-
icated phased array cardiac receiver coil. For LV function
imaging, during repeated breath holds, ECG-gated bal-
anced steady-state free-precession cine images were ob-
tained in short-axis orientation covering the left
ventricle from base to apex. For infarct analysis of the
myocardium, at least 10 min after administration of a
gadolinium-based contrast agent, late gadolinium-
enhanced (LGE) images were acquired using an inver-
sion recovery gradient-echo pulse sequence with slice
locations identical to the cine images.
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Segmental analysis
A 16-segment model, excluding the apex, was used to
analyze the segmental function in each patient. Endo- and
epicardial borders were manually outlined on all short-axis
cine slides on the end-diastolic and end-systolic images,
which has been shown to have a high reproducibility and re-
liability [9, 10]. SWT was defined as a percentage increase of
LV wall thickness during systole compared with diastole
[11]. Myocardial segments were considered dysfunctional if
SWT was less than 45% [12]. TEI was used to assess viabil-
ity, which was calculated by dividing the hyper enhanced
area by the total area in each of the 16 segments and
expressed as a percentage [13]. The TEI was divided into 2
groups: 0%–50% and >50% per segment. Four month
follow-up CMR was made according to the same protocol.
For each patient individual segments were assigned to one
of the major coronary arteries using the American Heart As-
sociation standardized myocardial segmentation and no-
menclature statement for tomographic imaging of the heart.
Using this standard model we determined whether segments
were supplied by the CTO, IRA or remote (related to the
baseline coronary anatomy scored by the angio corelab)
[14]. We studied the effect of CTO PCI on recovery of re-
gional SWT. To study changes over time baseline and
4 month CMR were compared. To study the effect of revas-
cularization on regional function, segments in the perfusion
territory of the CTO and IRA were analyzed separately. All
CMR images were analysed by an independent core labora-
tory, blinded for randomization outcome, (ClinFact Corelab,
Leiden) using dedicated software (QMass MR analytical
software version 7.6, Medis BV, Leiden, the Netherlands).
Quality control of the CMR data was performed by one per-
son (RN) and in case of poor imaging quality or artefacts
hampering imaging analysis, the CMR data were excluded.
Statistical analysis
Data are presented as mean ± standard deviation for con-
tinuous variables. Discrete variables were summarized as
frequencies and percentages. Baseline characteristics were
compared using the independent-samples T-test, or Fish-
er’s exact probability test in case of binary endpoints.
Changes in LVEF, LVEDV and infarct size within each
group were tested with paired student t-test. We evaluated
the recovery of regional segmental outcome (percentage
of SWT) in relation to the presence of dysfunctional seg-
ments at baseline and the presence of viability (TEI <50%)
at baseline. All outcomes were stratified for randomization
treatment. Because within 1 patient the regional function
in the different segments is strongly related and not an in-
dependent outcome, multilevel analysis was used (linear
regression) [11]. In the recovery of regional function ana-
lysis, a correction for baseline percentage of SWT was
made. All tests were 2 sided, and a p-value <0.05 was con-
sidered to indicate statistical significance.
Results
Baseline clinical and procedural characteristics
From the 302 patients randomized in the EXPLORE
Trial, 180 patients completed serial CMR (baseline and
4 months FU) and were included in the present analysis
(Fig. 1). The baseline characteristics of the 180 patients
included in this study and all patients in the EXPLORE
study are shown in Table 1. Sixty percent of the patients
in the CTO PCI group and 53% of the patients in the
no-CTO PCI had Rentrop grade 2–3 collaterals to the
CTO territory. Baseline characteristics were comparable
between the patients with serial CMR and patients with-
out serial CMR (Table 1). In 161 of the 180 patients
CMR quality was sufficient to assess regional function,
regional CMR data from 19 patients were excluded be-
cause of insufficient imaging quality.
Recovery of global left ventricular function
Recovery of global functional outcome was assessed in
180 patients with serial CMR. Compared to baseline, at
4 months LVEF increased with 4.6 ± 8.3% in patients
Fig. 1 Flowchart included patients. CMR = cardiovascular magnetic resonance, CTO = chronic total occlusion, PCI = percutaneous coronary intervention
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undergoing CTO PCI versus 3.8 ± 8.1% in the no-CTO
PCI group (p = 0.52), for LVEDV it was 5.5 ± 32.2 ml
versus 3.0 ± 25.7 ml (p = 0.57). There was no significant
difference in functional recovery between CTO PCI and
no-CTO PCI, also the decrease in infarct size was not
different between the 2 groups (Table 2).
Table 1 Baseline characteristics of STEMI patients with a CTO, stratified for the randomization outcome, in total group and in
patients with serial CMR
Serial CMR (n = 180) Total (n = 302)
CTO-PCI
(n = 80)
No CTO-PCI
(n = 100)
CTO-PCI
(n = 148)
No CTO-PCI
(n = 154)
P-value*
Age (years, mean, SD) 60(10) 60(10) 60(10) 60(10) 0.81
Male gender (%) 73(91) 84(84) 131(89) 126(82) 0.25
Diabetes (%) 13(16) 14(14) 22(15) 25(16) 0.75
Hypertension (%) 30(38) 48(48) 59(40) 69(45) 0.72
Family history of CAD (%) 32(40) 38(38) 66(45) 64(42) 0.10
Hypercholesterolaemia (%) 27(34) 33(33) 51(35) 52(34) 0.81
Current smoker (%) 40(50) 52(52) 77(52) 76(49) 0.97
Previous MI (%) 9(11) 17(17) 19(13) 24(16) 1.0
Previous PCI (%) 5(6) 13(13) 9(6) 16(10) 0.21
Previous stroke (%) 2(3) 3(3) 5(3) 6(4) 0.36
Primary PCI
Infarct related artery 0.77
Right coronary artery (%) 26(32) 31(31) 46(31) 47(31)
Left circumflex artery (%) 15(19) 30(30) 30(20) 43(28)
Left anterior descending artery/LM (%) 39(49) 39(39) 72(49) 64(42)
Three vessel disease (%) 34(43) 42(42) 62(42) 67(44) 0.91
MI SYNTAX score I (pre-PCI) 30(8) 29(10) 29(8) 29(10) 0.57
MI SYNTAX score II (wiring/balloon/aspiration) 28(8) 26(10) 27(8) 27(10) 0.62
Infarct size
Peak CK-MB (median, IQR) 133(38–198) 87(39–199) 130(39–272) 111(43–256) 0.14
Peak Troponin T(median, IQR) 3.1(1.3–7.8) 2.9(0.9–5.6) 3.1(1.1–7.8) 3.3(0.9–6.0) 0.23
LVEF before randomization a 41(12) 42(12) 41(11) 42(12) 0.97
CTO characteristics
Patients with multiple CTOs b 11(14) 13(13) 13(9) 22(14) 0.28
CTO related artery 0.61
Right coronary artery 32(40) 54(54) 46(43) 78(51)
Left circumflex artery 23(29) 24(24) 48(32) 37(24)
Left anterior descending artery 25(31) 22(22) 36(24) 39(25)
CTO Collaterals Rentrop Grade 2–3 48(60) 53(53) 80(54) 82(53) 0.30
Total J-CTO score (mean, SD) 2.0(1.1) 2.2(1.1) 2.1(1.1) 2.3(1.1) 0.07
Previously failed lesion 1(1) 4(4) 2(1) 4(3) 0.41
Blunt stump 17(21) 27(27) 33(22) 45(29) 0.51
Bending 50(63) 68(68) 98(66) 108(70) 0.26
Calcification 58(73) 81(81) 115(78) 132(86) 0.02
Occlusion length ≥ 20 mm 30(38) 43(43) 60(40) 68(44) 0.48
Data are number of patients (%), mean (SD) or median (IQR)
PCI percutaneous coronary intervention, CK-MB creatine kinase-MB isoenzyme, CTO chronic total occlusion, J-CTO Multicenter CTO registry of Japan, CMR
cardiovascular magnetic resonance
*p-value for patients with serial CMR versus patients without serial CMR
aImaging modality is CMR only; data available in 201 patients
bFor patients with multiple CTOs, the CTO supplying the largest amount of myocardium was defined as the main CTO
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Recovery of overall segmental wall thickening
A total of 2576 segments (n = 161 patients) were avail-
able for analysis of function (percentage SWT at 4 month
FU compared to baseline). Although a significant recov-
ery of SWT was seen over time, there was no difference
between the treatment arms (CTO PCI: 7 ± 30% versus
no-CTO PCI: 4 ± 30%, p = NS). In the segments that
were dysfunctional at baseline (n = 1511) no significant
recovery of SWT was seen in the CTO PCI group
compared to no-CTO PCI (16 ± 26% versus
13 ± 24% respectively, p = 0.06). In dysfunctional seg-
ments with TEI < 50% (n = 1127) there was also no
significant difference on the recovery of SWT after
CTO PCI compared to no-CTO PCI (16 ± 26% ver-
sus 13 ± 24%, p = 0.06). In dysfunctional segments
with TEI > 50% (n = 82) there was no significant dif-
ference in recovery of SWT between CTO PCI and
no-CTO PCI (11 ± 17% versus 12 ± 24%, p = NS).
Table 3 shows the change in percentage SWT in all
segments, in dysfunctional segments and in dysfunc-
tional segments with transmural extent of infarction
(TEI) < 50% and TEI >50% comparing CTO PCI
versus no-CTO PCI.
Recovery of regional segmental function of the CTO
territory
There were 845 segments in the CTO territory avail-
able for analysis (Table 3). In CTO territory segments
recovery of SWT was not significantly better in the
CTO PCI group compared to no-CTO PCI. In dys-
functional segments, the SWT recovery was most
noticeable: PCI of the CTO compared to a conserva-
tive approach resulted in a significantly better recov-
ery of SWT (17 ± 27% vs 11 ± 23%, p = 0.03). In
dysfunctional segments with TEI <50% in the CTO
territory CTO PCI resulted in a significantly better
recovery of SWT compared to no-CTO PCI
(17 ± 27% versus 11 ± 22%, p = 0.02). In dysfunc-
tional segments with TEI > 50% in the CTO territory
there was no significant difference in recovery after
CTO PCI compared to no-CTO PCI (16 ± 20% ver-
sus 3 ± 18%, p = NS). Figure 2 shows the recovery of
SWT in the CTO territory according to the treatment
arms.
Recovery of regional segmental function of the IRA
territory
There were 868 segments in the IRA territory available
for analysis. The highest recovery was seen in the seg-
ments in the IRA territory, however CTO PCI did not
lead to a better improvement of SWT. In dysfunctional
segments in the IRA territory the recovery was compar-
able between the treatment groups (Table 3).
Influence of collaterals to the CTO territory on regional
function
In the CTO territory the recovery of SWT of segments
was compared in patients with Rentrop grade 2–3 versus
grade 0–1 collaterals to the CTO territory. Baseline
SWT of all the segments in the CTO territory was not
different between the patients with Rentrop grade 2–3
collaterals (43 ± 32%) and the patients with grade 0–1
collaterals to the CTO (41 ± 36%) (difference in baseline
SWT: p = NS). In dysfunctional segments in the CTO
territory recovery of SWT was better in the patients with
Rentrop grade 2–3 collaterals compared to grade 0–1
collaterals (16 ± 26% versus 11 ± 24%, p = 0.04) (Fig. 3).
However there was no significant interaction of collat-
eral grading on the effect of CTO PCI on recovery of
SWT in the CTO territory (p-value for interaction
p = 0.74).
Discussion
Impact of CTO PCI on regional myocardial function
This EXPLORE CMR study is the first randomized study
evaluating the effect of CTO PCI on the recovery of re-
gional LV function in STEMI patients with a concurrent
CTO at 4 month FU. Furthermore this is the only study
that compares an invasive treatment strategy with a con-
trol group not undergoing CTO PCI within 4 months.
In addition this sub-analysis is performed in the largest
cohort of serial CMR data in the CTO field. The key
finding of our study is that revascularization of the dys-
functional myocardium supplied by the CTO results in a
greater recovery of regional LV function from baseline to
Table 2 Serial CMR outcomes: Recovery of global functional
outcomes in the total CMR population
Total CMR population CTO PCI
(n = 80)
No-CTO PCI
(n = 100)
P-value
Left ventricular ejection fraction (%)
Baseline 40.6 (11.8) 41.7 (12.1) 0.55
4 months FU 45.3 (11.6) 45.5 (11.8) 0.87
Δ LVEF 4.6 (8.3) 3.8 (8.1) 0.52
Left ventricular end-diastolic volume (ml)
Baseline 210.1 (53.4) 209.5 (55.1) 0.95
4 months FU 215.6 (54.6) 212.5 (53.9) 0.71
Δ LVEDV 5.5 (32.4) 3.0 (25.7) 0.57
Infarct size (g) a
Baseline 11.7 (10.5) 11.9(11.1) 0.94
4 months FU 7.5 (6.4) 7.1 (5.4) 0.70
Δ Infarct size −4.3 (8.0) −4.8 (8.6) 0.72
Data are number of patients (n)
CMR cardiac magnetic resonance imaging, CTO chronic total occlusion, PCI
percutaneous coronary intervention, LAD left anterior descending artery, LVEF
left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume
aInfarct data available in 60 and 68 patients
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4 months FU, when compared with no revascularization
of the CTO territory.
The effect of CTO PCI on regional myocardial func-
tion is sparsely investigated. Previous smaller studies, all
without a control group, have suggested an improve-
ment of regional wall motion after successful CTO PCI,
especially in initially dysfunctional segments. Further-
more, these studies showed that improvement in the
CTO territory was only observed in segments without
TEI (viable segments) [7]. Kirschbaum et al. also sug-
gested that in elective CTO patients undergoing CTO
PCI early and late improvement of regional LV function
was related to the percentage of TEI of the CTO area
[6]. Another small study showed that the extent of dys-
functional but viable myocardium at baseline was related
to the improvement of SWT after CTO PCI [15]. The
aforementioned studies were all done in elective and
only successful CTO PCI patients. Our study confirms
previous studies. Overall, the benefit of CTO PCI is
most evident in initially dysfunctional but viable seg-
ments (TEI < 50%). In dysfunctional segments with a
TEI >50% there was no significant difference in im-
provement after CTO PCI compared to no-CTO PCI,
although number of segments are small. However previ-
ous studies showed that the diagnostic performance of
contrast enhanced CMR is less evident in the segments
with intermediate TEI [6, 15]. Additional viability testing
with stress (dobutamine) perfusion CMR leads to better
prediction of improvement in dysfunctional myocardium
after CTO PCI than the parameter TEI alone [5]. The
marked improvement of regional function in dysfunc-
tional but viable segments, emphasizes the need for ran-
domized controlled trials to investigate the optimal CMR
assessment of dysfunctional and viable myocardium and
Fig. 2 Changes in regional left ventricular function in segments in the CTO territory, comparing CTO PCI versus no-CTO PCI. Change in percentage
segmental wall thickening (SWT) in all segments and dysfunctional segments in the CTO territory (a and b). Recovery of SWT was compared between
baseline and 4 month follow-up in segments and between CTO PCI and no-CTO PCI (*)
Fig. 3 Changes in regional left ventricular function in segments in the CTO territory in Rentrop grade 2–3 collaterals versus grade 0–1 collaterals,
comparing CTO PCI versus no-CTO PCI. Change in percentage segmental wall thickening (SWT) in all segments (a) and dysfunctional segments
(b) in the CTO territory comparing Rentrop grade 2–3 collaterals versus grade 0–1 collaterals. Recovery of SWT was compared between baseline
and 4 month follow-up
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which CMR parameters are able to accurately assess
which patients will benefit from CTO PCI.
In both treatment groups there was an increase of
SWT at 4 months, probably due to recovery of the
stunned myocardium, caused by acute interruption of
blood flow. Recovery of stunned myocardium will lead
to (partial) recovery of LV function, typically over hours
to days [16]. In a chronic situation recovery is related to
the extent of hibernating myocardium of the targeted
territory, and usually will only improve after restoration
of blood flow. Hibernating myocardium is defined as
myocardium that has adapted to the chronic reduction
in blood flow in order to preclude actual infarction, but
resulting in loss of myocardial contraction [17]. Previous
studies have shown that functional recovery of hiberna-
ting myocardium can vary from 10 days, in case of
minor structural abnormalities, up to 14 months [18,
19]. Therefore it is possible that, in our unique popula-
tion, recovery was delayed and that the functional recov-
ery was incomplete at 4 months. In a previous study of
patients with chronic ischemic LV dysfunction there was
a positive relation between the amount of dysfunctional
but viable myocardium at baseline and improvement in
LVEF at six months follow-up. In this study a cut-of
value of ≥55% for viability was able to predict both the
long-term significant improvement in LVEF and the re-
verse LV remodeling [20]. A previous study in patients
with coronary artery disease and with wall motion ab-
normalities, but without infarction, showed that revascu-
larization of the hibernating myocardium results in
reverse remodeling and that the extent of this remodel-
ing was related to the number of viable segments [21].
This reverse remodeling can lead to improvement in
outcome and less future cardiac events. Therefore longer
follow-up CMR studies are needed to assess the effect of
regional recovery on global LV function in STEMI pa-
tients with a CTO.
Furthermore, the effect of CTO PCI on regional LV
function might be associated with other positive effects
of CTO PCI such as prevention of arrhythmias. Presence
of a CTO affects the electrophysiological properties of
the myocardium and restoration of antegrade blood flow
to the ischemic and dysfunctional CTO territory might
enhance electrical stability. In ICD patients with a CTO,
compared to patients without a CTO, more ICD therapy
was delivered [22]. This indicates that the persistent is-
chemic zone of the CTO territory, consisting of re-entry
circuits and myocardial cells with abnormal automaticity
at the border zone of previous MI, is a substrate for such
arrhythmias [23]. In elective setting a significant de-
crease of both corrected and uncorrected QT-interval
dispersion on electrocardiography was directly seen after
successful CTO PCI compared to failed CTO PCI, indi-
cating improvement of regional myocardial repolarization
[24]. This indicates that the hibernating myocardium in
the CTO territory might improve in repolarization dur-
ation shortly after successful CTO PCI. Therefore the ef-
fect of revascularization on regional LV recovery might
also be true for restoration of repolarization duration im-
mediately after CTO PCI while more time is needed for
the recovery on a more mechanical level (contractile func-
tion). This effect on electrophysiological properties might
in turn lead to a reduction in incidence of arrhythmia and
sudden death, even though there is little or no effect on
global functional outcome. However what the timing and
the prognostic effect of this electrical recovery actually is
needs further exploration.
In our study segments in the CTO territory showed
better recovery of SWT in case of Rentrop grade 2–3
collaterals compared to grade 0–1 collaterals. In single
CTO patients without a prior MI, patients with Rentrop
grade 3 collaterals showed less resting regional wall ab-
normalities with minimal resting perfusion abnormalities
on myocardial perfusion SPECT. However, most patients
did have stress induced perfusion defects. These findings
suggest that chronic stunning rather than true hiberna-
tion is the primary cause of regional wall abnormalities
[25]. This stunned myocardium will recover faster than
the hibernating myocardium, theoretically leading to
earlier functional recovery and probably improved out-
comes. In a previous study of STEMI patients with a
concurrent CTO survival was better in the patients with
well- versus poorly-developed collaterals [26]. However
the exact role of collaterals on LV functional recovery
and outcome remains controversial and results are
conflicting.
Study limitations
There are several limitations applicable to this study.
Our sample size might be too small to detect differences,
especially in the various subgroups. Unfortunately, base-
line CMR was not performed in all patients included in
the EXPLORE trial, though the baseline characteristics
are comparable between patients with and those without
serial CMR. Overall the patients included in the study
had a moderately reduced LVEF, therefore the results
might not be applicable to all patients, especially the pa-
tients with a severely reduced LVEF or patients present-
ing with cardiogenic shock. However SWT analysis was
a predefined secondary endpoint of the EXPLORE trial.
Conclusions
In dysfunctional segments in the CTO territory, CTO
PCI compared with no-CTO PCI was associated with a
marked improvement of regional function. Furthermore,
in dysfunctional segments with TEI < 50% in the CTO
territory CTO PCI compared to no-CTO PCI resulted
in a better recovery of SWT, while in dysfunctional
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segments with TEI > 50% there was no treatment effect
on regional function. Furthermore patients with grade
2–3 collaterals compared to grade 0–1 collaterals to the
CTO showed a significantly better SWT recovery in the
dysfunctional segments. Further studies are needed to
investigate the effect of this regional improvement on
clinical outcome and how to use CMR in selecting
patients for CTO PCI after STEMI.
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